Harvard Bioscience (NASDAQ:HBIO – Get Free Report) and Charles River Laboratories International (NYSE:CRL – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.
Profitability
This table compares Harvard Bioscience and Charles River Laboratories International’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Harvard Bioscience | -13.20% | -43.94% | -5.15% |
| Charles River Laboratories International | 1.01% | 16.95% | 6.93% |
Insider & Institutional Ownership
80.9% of Harvard Bioscience shares are owned by institutional investors. Comparatively, 98.9% of Charles River Laboratories International shares are owned by institutional investors. 17.0% of Harvard Bioscience shares are owned by insiders. Comparatively, 1.3% of Charles River Laboratories International shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a summary of current ratings and target prices for Harvard Bioscience and Charles River Laboratories International, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Harvard Bioscience | 1 | 3 | 1 | 0 | 2.00 |
| Charles River Laboratories International | 1 | 3 | 12 | 0 | 2.69 |
Harvard Bioscience currently has a consensus target price of $6.75, suggesting a potential downside of 25.66%. Charles River Laboratories International has a consensus target price of $311.67, suggesting a potential downside of 6.33%. Given Charles River Laboratories International’s stronger consensus rating and higher probable upside, analysts clearly believe Charles River Laboratories International is more favorable than Harvard Bioscience.
Valuation and Earnings
This table compares Harvard Bioscience and Charles River Laboratories International”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Harvard Bioscience | $86.55 million | 0.48 | -$56.70 million | ($2.59) | -3.51 |
| Charles River Laboratories International | $4.02 billion | 3.97 | -$144.34 million | $0.91 | 365.62 |
Harvard Bioscience has higher earnings, but lower revenue than Charles River Laboratories International. Harvard Bioscience is trading at a lower price-to-earnings ratio than Charles River Laboratories International, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Harvard Bioscience has a beta of 1.47, meaning that its share price is 47% more volatile than the S&P 500. Comparatively, Charles River Laboratories International has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500.
Summary
Charles River Laboratories International beats Harvard Bioscience on 11 of the 14 factors compared between the two stocks.
About Harvard Bioscience
Harvard Bioscience, Inc. develops, manufactures and sells scientific instruments and equipment used in life science research. Its products support work in areas such as physiology, electrophysiology and preclinical research, and are used by academic and government institutions, biotechnology and pharmaceutical companies, and contract research organizations. The company’s offerings include laboratory instruments, equipment and related consumables, including systems for measuring biological activity and studying tissues, organs and cells.
About Charles River Laboratories International
Charles River Laboratories International is a contract research organization that supports pharmaceutical and biotechnology companies, as well as academic and government researchers, in developing medicines and advancing scientific research. Its services span the drug development process, from early discovery and preclinical research to manufacturing support. The company’s offerings include research models and related services, drug discovery and safety assessment, and manufacturing solutions. These may include laboratory animal models, laboratory testing, bioanalysis, and support for the production of products used in the development of pharmaceuticals and biologics.
Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
